| scholarly article | Q13442814 |
| P50 | author | Stephen Fox | Q30506440 |
| Scott H Kaufmann | Q40592168 | ||
| Matthew Wakefield | Q42853296 | ||
| David Bowtell | Q47451431 | ||
| Kathryn Alsop | Q56840332 | ||
| Karla J Hutt | Q61096480 | ||
| P2093 | author name string | Dariush Etemadmoghadam | |
| Elizabeth M Swisher | |||
| Laura Galletta | |||
| Gillian Mitchell | |||
| Clare L Scott | |||
| Australian Ovarian Cancer Study | |||
| Jan Pyman | |||
| Jeffrey B Kerr | |||
| Orla McNally | |||
| Sumitra Ananda | |||
| Lynne Hartley | |||
| Valerie Heong | |||
| Michele Cook | |||
| Emma Boehm | |||
| Lauren McShane | |||
| Marisol Harrell | |||
| Monique D Topp | |||
| P2860 | cites work | Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing | Q24632270 |
| Efficient tumour formation by single human melanoma cells | Q24648938 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Resistance to therapy caused by intragenic deletion in BRCA2 | Q28268169 | ||
| The landscape of somatic copy-number alteration across human cancers | Q29547648 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence | Q29620428 | ||
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup | Q30436714 | ||
| Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer | Q83145997 | ||
| Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer | Q33754744 | ||
| Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers | Q33886925 | ||
| Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors | Q33896961 | ||
| BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation | Q33930051 | ||
| Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. | Q33944203 | ||
| Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary | Q34103978 | ||
| Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells | Q34836634 | ||
| Genetic predisposition to colorectal cancer | Q35930688 | ||
| Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. | Q35999582 | ||
| Rethinking ovarian cancer: recommendations for improving outcomes | Q36050883 | ||
| BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group | Q36145443 | ||
| A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes | Q36492194 | ||
| Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers | Q36958682 | ||
| Evaluating cell lines as tumour models by comparison of genomic profiles | Q37025950 | ||
| Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics | Q37431491 | ||
| Update of randomized trials in first-line treatment | Q37969715 | ||
| Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. | Q39542474 | ||
| Development of a syngeneic mouse model for events related to ovarian cancer | Q40888613 | ||
| Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy | Q46244368 | ||
| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing | Q47163678 | ||
| Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 | ||
| Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor | Q58053593 | ||
| Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts | Q64387019 | ||
| Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models | Q81120942 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | platinum | Q880 |
| ovarian cancer | Q172341 | ||
| patient | Q181600 | ||
| xenograft | Q64148587 | ||
| P304 | page(s) | 656-668 | |
| P577 | publication date | 2014-01-24 | |
| P1433 | published in | Molecular Oncology | Q2190736 |
| P1476 | title | Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts | |
| P478 | volume | 8 |
| Q48360452 | A community-based model of rapid autopsy in end-stage cancer patients |
| Q35961381 | AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer |
| Q92620214 | Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models |
| Q92476256 | Applications of patient-derived tumor xenograft models and tumor organoids |
| Q51441965 | B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy |
| Q36123789 | Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods |
| Q92757507 | Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations |
| Q89649803 | CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes |
| Q95840116 | CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer |
| Q58694894 | Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response |
| Q42344756 | Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts |
| Q48569329 | Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. |
| Q35592388 | Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft |
| Q64969004 | Current Status of Patient-Derived Ovarian Cancer Models. |
| Q26783909 | Emerging and Evolving Ovarian Cancer Animal Models |
| Q36772043 | Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs |
| Q52851743 | Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. |
| Q37353774 | Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways |
| Q37272622 | Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma |
| Q98777898 | Human-Derived Model Systems in Gynecological Cancer Research |
| Q36436803 | It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research. |
| Q28393224 | MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas |
| Q36751575 | MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. |
| Q59126243 | Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma |
| Q33641924 | Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems |
| Q26786724 | Molecular and clinical implementations of ovarian cancer mouse avatar models |
| Q59209822 | Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response |
| Q48124146 | Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells |
| Q38508812 | Ovarian and cervical cancer patient derived xenografts: The past, present, and future. |
| Q36414048 | Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure |
| Q89782341 | PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma |
| Q38756596 | Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib |
| Q58768056 | Patient-Derived Xenograft Models for Endometrial Cancer Research |
| Q38722976 | Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. |
| Q34141193 | Patient-derived xenograft models in gynecologic malignancies |
| Q27026531 | Patient-derived xenograft models of breast cancer and their predictive power |
| Q28067191 | Patient-derived xenografts: a relevant preclinical model for drug development |
| Q38254072 | Poised epigenetic states and acquired drug resistance in cancer |
| Q28083993 | Prioritizing therapeutic targets using patient-derived xenograft models |
| Q37620476 | Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. |
| Q26780387 | Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer |
| Q41691425 | Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma |
| Q38605020 | Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. |
| Q40810058 | TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer. |
| Q61815424 | Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy |
| Q52811875 | Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models |
| Q47553013 | The latest animal models of ovarian cancer for novel drug discovery |
| Q49544632 | Xenograft as In Vivo Experimental Model |
| Q37295618 | Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. |
Search more.